MARK2 and pulmonary fibrosis: The serine/threonine kinase-protein kinase B (Akt) pathway is activated in pulmonary fibrosis, and the inhibition of this pathway reduces fibroblast to myofibroblast differentiation and ameliorates pulmonary fibrosis [13,14,16].